Cryptococcus neoformans-Cryptococcus gattii Species Complex: an International Study of Wild-Type Susceptibility Endpoint Distributions and Epidemiological Cutoff Values for Amphotericin B and Flucytosine

Extensive Genetic Diversity within the Dutch Clinical Cryptococcus neoformans Population

(2012) Ferry Hagen et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Correlation of antifungal susceptibility and molecular type within theCryptococcus neoformans/C. gattiispecies complex

(2012) Luciana Trilles et al.   MEDICAL MYCOLOGY

Correlation of Susceptibility of Cryptococcus neoformans to Amphotericin B with Clinical Outcome

(2011) R. A. Larsen et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Wild-Type MIC Distributions and Epidemiological Cutoff Values for Caspofungin and Aspergillus spp. for the CLSI Broth Microdilution Method (M38-A2 Document)

(2011) A. Espinel-Ingroff et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Wild-Type MIC Distributions and Epidemiological Cutoff Values for Amphotericin B and Aspergillus spp. for the CLSI Broth Microdilution Method (M38-A2 Document)

(2011) A. Espinel-Ingroff et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Cryptococcus gattii in the United States: Clinical Aspects of Infection With an Emerging Pathogen

(2011) J. R. Harris et al.   CLINICAL INFECTIOUS DISEASES

In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii serotype B from north-western India

(2011) A. Chowdhary et al.   JOURNAL OF MEDICAL MICROBIOLOGY

A Diverse Population of Cryptococcus gattii Molecular Type VGIII in Southern Californian HIV/AIDS Patients

(2011) Edmond J. Byrnes et al.   PLoS Pathogens

In Vitro Antifungal Susceptibilities and Amplified Fragment Length Polymorphism Genotyping of a Worldwide Collection of 350 Clinical, Veterinary, and Environmental Cryptococcus gattii Isolates

(2010) F. Hagen et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America

(2010) John R. Perfect et al.   CLINICAL INFECTIOUS DISEASES

Epidemiology of Invasive Mycoses in North America

(2010) Michael A. Pfaller et al.   CRITICAL REVIEWS IN MICROBIOLOGY

Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: Time for harmonization of CLSI and EUCAST broth microdilution methods

(2010) M.A. Pfaller et al.   DRUG RESISTANCE UPDATES

Wild-Type MIC Distributions and Epidemiological Cutoff Values for Posaconazole and Voriconazole and Candida spp. as Determined by 24-Hour CLSI Broth Microdilution

(2010) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Wild-Type MIC Distributions and Epidemiological Cutoff Values for the Triazoles and Six Aspergillus spp. for the CLSI Broth Microdilution Method (M38-A2 Document)

(2010) A. Espinel-Ingroff et al.   JOURNAL OF CLINICAL MICROBIOLOGY

In Vitro Susceptibility of the Yeast Pathogen Cryptococcus to Fluconazole and Other Azoles Varies with Molecular Genotype

(2010) H. S. Chong et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Emergence and Pathogenicity of Highly Virulent Cryptococcus gattii Genotypes in the Northwest United States

(2010) Edmond J. Byrnes et al.   PLoS Pathogens

A Long Journey from Minimum Inhibitory Concentration Testing to Clinically Predictive Breakpoints: Deterministic and Probabilistic Approaches in Deriving Breakpoints

(2009) A. Dalhoff et al.   INFECTION

Wild-Type MIC Distributions and Epidemiological Cutoff Values for the Echinocandins andCandidaspp.

(2009) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Correlation of Genotype and In Vitro Susceptibilities of Cryptococcus gattii Strains from the Pacific Northwest of the United States

(2009) N. Iqbal et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Wild-Type MIC Distribution and Epidemiological Cutoff Values for Aspergillus fumigatus and Three Triazoles as Determined by the Clinical and Laboratory Standards Institute Broth Microdilution Methods

(2009) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Diversidad del complejo de especies Cryptococcus neoformans-Cryptococcus gattii

(2009) Marjan Bovers et al.   REVISTA IBEROAMERICANA DE MICOLOGIA

Mecanismos de resistencia a los antifúngicos: levaduras y hongos filamentosos

(2009) Ana Espinel-Ingroff   REVISTA IBEROAMERICANA DE MICOLOGIA

Antifungal Susceptibilities among Different Serotypes of Cryptococcus gattii and Cryptococcus neoformans

(2008) G. R. Thompson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Activity of the New Azole Isavuconazole (BAL4815) Compared with Six Other Antifungal Agents against 162 Cryptococcus neoformans Isolates from Cuba

(2008) M.-T. Illnait-Zaragozi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Epidemiological Cutoffs and Cross-Resistance to Azole Drugs in Aspergillus fumigatus

(2008) J. L. Rodriguez-Tudela et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In vitro susceptibility of Cryptococcus gattii clinical isolates

(2008) A. Gomez-Lopez et al.   CLINICAL MICROBIOLOGY AND INFECTION

Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-Year Analysis of Susceptibilities of Noncandidal Yeast Species to Fluconazole and Voriconazole Determined by CLSI Standardized Disk Diffusion Testing

(2008) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Regional pattern of the molecular types of Cryptococcus neoformans and Cryptococcus gattii in Brazil

(2008) Luciana Trilles et al.   MEMORIAS DO INSTITUTO OSWALDO CRUZ

Resistance to Antifungal Agents: Mechanisms and Clinical Impact

(2007) Z. A. Kanafani et al.   CLINICAL INFECTIOUS DISEASES